Smart Beta ETF report for IBD
Inspire Corporate Bond ETF (IBD) โ Live Session & Technical Brief
Updated Nov 22, 2026 5:46 AM ET ยท Prev Close $23.17
Session Regime & Catalyst Assessment
64% Signal ConvictionControlled Session Consolidation (-0.09%) in Equities
Inspire Corporate Bond ETF (Ibd) is trading within a tight intraday band at $23.15 (-0.09%, 0.97x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, IBD is outperforming the S&P 500 by +3.55%. 14-day RSI stands at 46.5, keeping momentum in a bearish regime.
Smart Beta ETF report for IBD
Price ($23.15) trades relative to 20-day SMA ($23.21) and 50-day SMA ($23.18).
Market & Sector Relative Strength
IBD outperforming the S&P 500 by +3.55%Recent IBD Catalyst Headlines
Verified WireInspire Investing is pleased to announce that the Inspire Corporate Bond ETF NYSE Ibd has been awarded a 5-star Overall Morningstar Rating for the 5-year period out of 155 Corporate Bond funds as of 7 31 26. Morningstar'
Inspire Investing is pleased to announce that the Inspire International ETF NYSE Wwjd has surpassed 500 million in assets under management, marking a major milestone for the faith-based ETF.
Inspire Investing, the world's largest provider of Christian ETFs, reported expense ratio reductions on five of its exchange traded funds. These reductions range from 2.7 to 7.6 for an overall average decrease of 5.3 . T
1โ3 Day Expected Range & Key Level
54% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $23.21 (20-day SMA resistance) for directional breakout confirmation.
Technical Regime (IBD)
MIXED MA TRENDRetail & Crowd Sentiment
BullishAbout Inspire Corporate Bond ETF
Get Instant IBD Catalyst Alerts
Receive an email alert when IBD triggers an unusual volume breakout, options sweep, or rating shift.
IBD Session & Catalyst FAQ
Why is IBD stock trading near flat today?
Inspire Corporate Bond ETF (Ibd) is trading within a tight intraday band at $23.15 (-0.09%, 0.97x relative volume), signaling orderly institutional price discovery without an outlier shock. Relative to benchmarks, IBD is outperforming the S&P 500 by +3.55%. 14-day RSI stands at 46.5, keeping momentum in a bearish regime.
Is IBD stock a buy or sell right now?
Today's session carries a 64% catalyst conviction score on 0.97x relative volume (moderate participation). Our multi-factor model currently rates IBD as STRONG BUY. Review full valuation, quality, and timing signals on the IBD Buy or Sell Decision Brief โ
What is IBD's intrinsic value and expected trading range?
At $23.15, IBD's modeled 1-to-3 session range is $22.64 โ $23.66, with a key inflection level at $23.21 (20-day SMA resistance). Compare current price against multi-year cash flow projections in the IBD Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
What do RSI and moving averages signal for IBD?
RSI at 46.5 reflects soft below-midline momentum. IBD trades at $23.15 relative to its 20-day SMA ($23.21) and 50-day SMA ($23.18), reflecting a mixed moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.